Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?

The overwhelming key here is to determine if this is truly mast cell activation syndrome, and, if so, what type. Multiple published studies have born out what many of us who see patients for concern for MCAS-- that only a very small percentage of those with the label or concern for the label actuall...